Publications by authors named "Alexander Neuhof"

Claim this Profile
O
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma.
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof

Future Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE Trial.
Matthias Stelljes, Anjali S Advani, Daniel J DeAngelo, Tao Wang, Alexander Neuhof

Clin Lymphoma Myeloma Leuk· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterizing the Patient Journey in Multiple Myeloma: Qualitative Review.
Matthew Lyall, Rebecca Crawford, Timothy Bell, Carla Mamolo, Alexander Neuhof

JMIR Cancer· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response rates and minimal residual disease outcomes as potential surrogates for progression-free survival in newly diagnosed multiple myeloma.
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof

PLoS One· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22.
Hagop M Kantarjian, Wendy Stock, Ryan D Cassaday, Daniel J DeAngelo, Elias Jabbour, Alexander Neuhof

Clin Cancer Res· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin.
Ryan D Cassaday, David I Marks, Daniel J DeAngelo, Elias J Jabbour, Anjali S Advani, Alexander Neuhof

Br J Haematol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database.
Elias Jabbour, Matthias Stelljes, Anjali S Advani, Daniel J DeAngelo, Nicola Gökbuget, Alexander Neuhof

Leuk Lymphoma· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inotuzumab ozogamicin for relapsed/refractory acute lymphoblastic leukemia: outcomes by disease burden.
Daniel J DeAngelo, Anjali S Advani, David I Marks, Matthias Stelljes, Michaela Liedtke, Alexander Neuhof

Blood Cancer J· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Elias Jabbour, Nicola Gökbuget, Anjali Advani, Matthias Stelljes, Wendy Stock, Alexander Neuhof

Leuk Res· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis